China SXT Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	1.14	1.74	1.93	1.97	2.6
Revenue Growth	-34.63%	-9.73%	-2.19%	-24.23%	-45.53%
Cost of Revenue	0.89	1.37	1.37	1.55	1.35
Gross Profit	0.25	0.37	0.55	0.43	1.25
Selling, General & Admin	7.37	3.05	2.65	5.68	6.44
Operating Expenses	7.37	3.05	2.65	5.68	6.44
Operating Income	-7.12	-2.68	-2.09	-5.26	-5.19
Interest Expense	-0.06	-0.65	-0.55	-0.48	-0.04
Interest & Investment Income	-	0	0.01	-	0
Other Non Operating Income (Expenses)	0.98	0.03	-0.04	0.15	-0.18
EBT Excluding Unusual Items	-6.21	-3.3	-2.68	-5.59	-5.41
Asset Writedown	-	-	-0.42	-0.35	-
Pretax Income	-6.21	-3.3	-3.1	-5.93	-5.41
Income Tax Expense	-	-	-	-	0.33
Net Income	-6.21	-3.3	-3.1	-5.93	-5.74
Net Income to Common	-6.21	-3.3	-3.1	-5.93	-5.74
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	-	-	-	-	2
Shares Outstanding (Diluted)	-	-	-	-	2
Shares Change	-	-	-	-	-86.91%
EPS (Basic)	-	-	-	-	-2.82
EPS (Diluted)	-	-	-	-	-2.82
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-4.02	-2.35	-1.94	-0.15	0.21
Free Cash Flow Per Share	-	-	-	-	0.10
Gross Margin	21.85%	21.11%	28.73%	21.62%	48.10%
Operating Margin	-625.89%	-153.97%	-108.49%	-266.68%	-199.43%
Profit Margin	-545.24%	-189.77%	-160.67%	-301.00%	-220.43%
Free Cash Flow Margin	-353.01%	-134.83%	-100.34%	-7.68%	7.91%
EBITDA	-7.05	-2.6	-1.89	-5.01	-4.87
EBITDA Margin	-	-149.24%	-97.95%	-253.99%	-187.13%
D&A For EBITDA	0.07	0.08	0.2	0.25	0.32
EBIT	-7.12	-2.68	-2.09	-5.26	-5.19
EBIT Margin	-	-153.97%	-108.49%	-266.68%	-199.43%
Revenue as Reported	1.14	1.74	1.93	1.97	2.6

SEC Filings: 10-K · 10-Q